Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review
BJU International · 2025
DOI: 10.1111/bju.16536 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BJU International, 2025. Verfasst von Jianliang Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Australia. Hauptthemen laut MEDLINE: Testicular Neoplasms, Lymph Node Excision, Seminoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objective
To conduct a systematic review of the current literature to determine the current role of primary retroperitoneal lymph node dissection (RPLND) in stage II testicular seminoma and its associated oncological, functional and peri‐operative outcomes. Materials and Methods A comprehensive literature search was conducted in Medline, Embase, and Scopus for publications from inception until November 2023. The systematic review was registered on PROSPERO (ID CRD42023449781), was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines and utilised the Methodological Index for Non‐Randomised Studies (MINORS) tool.
Results
Six studies involving 385 patients were analysed, with 48.5% clinical stage IIA and 51.5% stage IIB seminomas. The patients’ mean (range) age was 37 (20–64) years. The median operation time was 187 min, median estimated blood loss was 150 mL and median length of hospital stay was 4 days. In all, 6.1% of patients developed complications that were greater or equal to Clavien–Dindo grade 3. Only four studies reported on anejaculation rate (median: 4.9%). Only one study had long‐term data, demonstrating a 92% 5‐year overall survival for stage IIA/B disease treated with RPLND. The remaining five studies had a median follow‐up of between 18.5 and 37 months and reported a mean recurrence rate of 15.6%. Most recurrences (78%) were not within the field of RPLND. Recurrence was associated with higher clinical and pathological lymph node stage, and metachronous or delayed development of retroperitoneal lymphadenopathy (initially stage I disease, as opposed to de novo stage IIA/B disease).
Discussion
Primary RPLND, performed by experienced surgeons, has good peri‐operative outcomes. Recurrence is more common than with standard treatment, but long‐term survival and functional data are limited, although promising.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Australia.
- Department of Urology, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
- Department of Surgery, University of Melbourne, Melbourne, Australia.
- Department of Urology, The Queen Elizabeth Hospital, Woodville, Australia.
- Discipline of Surgery, University of Adelaide, Adelaide, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
ORCID-Profile: Jianliang Liu, Benjamin Thomas, Nathan Lawrentschuk
Zitieren
APA
Liu, J., Hiwase, M., Woon, D. T. S., Thomas, B., Tran, B., & Lawrentschuk, N. (2025). Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review. BJU International. https://doi.org/10.1111/bju.16536
Vancouver
Liu J, Hiwase M, Woon DTS, Thomas B, Tran B, Lawrentschuk N. Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review. BJU International. 2025. doi:10.1111/bju.16536
BibTeX
@article{Liu2025,
author = {Liu, Jianliang and Hiwase, Mrunal and Woon, Dixon T S and Thomas, Benjamin and Tran, Ben and Lawrentschuk, Nathan},
title = {Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16536}
}
EUVIMED